Throm Robert E, Ouma Annastasia A, Zhou Sheng, Chandrasekaran Anantharaman, Lockey Timothy, Greene Michael, De Ravin Suk See, Moayeri Morvarid, Malech Harry L, Sorrentino Brian P, Gray John T
Department of Hematology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Blood. 2009 May 21;113(21):5104-10. doi: 10.1182/blood-2008-11-191049. Epub 2009 Mar 13.
Retroviral vectors containing internal promoters, chromatin insulators, and self-inactivating (SIN) long terminal repeats (LTRs) may have significantly reduced genotoxicity relative to the conventional retroviral vectors used in recent, otherwise successful clinical trials. Large-scale production of such vectors is problematic, however, as the introduction of SIN vectors into packaging cells cannot be accomplished with the traditional method of viral transduction. We have derived a set of packaging cell lines for HIV-based lentiviral vectors and developed a novel concatemeric array transfection technique for the introduction of SIN vector genomes devoid of enhancer and promoter sequences in the LTR. We used this method to derive a producer cell clone for a SIN lentiviral vector expressing green fluorescent protein, which when grown in a bioreactor generated more than 20 L of supernatant with titers above 10(7) transducing units (TU) per milliliter. Further refinement of our technique enabled the rapid generation of whole populations of stably transformed cells that produced similar titers. Finally, we describe the construction of an insulated, SIN lentiviral vector encoding the human interleukin 2 receptor common gamma chain (IL2RG) gene and the efficient derivation of cloned producer cells that generate supernatants with titers greater than 5 x 10(7) TU/mL and that are suitable for use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).
与近期在其他方面取得成功的临床试验中使用的传统逆转录病毒载体相比,含有内部启动子、染色质绝缘子和自失活(SIN)长末端重复序列(LTR)的逆转录病毒载体可能具有显著降低的基因毒性。然而,此类载体的大规模生产存在问题,因为将SIN载体引入包装细胞无法通过传统的病毒转导方法实现。我们已获得了一组用于基于HIV的慢病毒载体的包装细胞系,并开发了一种新型的串联阵列转染技术,用于引入LTR中缺乏增强子和启动子序列的SIN载体基因组。我们使用这种方法获得了一个表达绿色荧光蛋白的SIN慢病毒载体的生产细胞克隆,该克隆在生物反应器中生长时可产生超过20升的上清液,滴度高于每毫升10^7转导单位(TU)。我们技术的进一步改进能够快速产生稳定转化细胞的整个群体,其产生的滴度相似。最后,我们描述了一种编码人白细胞介素2受体共同γ链(IL2RG)基因的绝缘SIN慢病毒载体的构建,以及高效获得克隆生产细胞的方法,这些细胞产生的上清液滴度大于5×10^7 TU/mL,适用于X连锁重症联合免疫缺陷(SCID-X1)的临床试验。